Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors
Noboru Yamamoto, Takafumi Koyama, Toshio Shimizu, Akiko Todaka, Takeshi Kawakami, Damijan Eržen, Akiko Sarashina, Bin Li, Jianrui Hou, Kentaro Yamazaki
Topics & Concepts
MedicineMaximum tolerated doseAdverse effectInternal medicineProteinuriaClinical endpointGastroenterologyPharmacologyClinical trialKidneyAngiogenesis and VEGF in CancerMonoclonal and Polyclonal Antibodies ResearchCancer Research and Treatments